In conclusion, P + T + taxane appears to be associated with a better long-term outcome compared with T-DM1 in HER2+ metastatic breast tumors relapsed during or within 12 months from the administration of (neo)adjuvant CT and/or trastuzumab. Here, ERBB2 is linked to breast neoplasm.